Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxothiazolidine carboxylate

Drug Profile

Oxothiazolidine carboxylate

Alternative Names: OTC; OTZ; Procysteine

Latest Information Update: 17 Feb 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nonindustrial source
  • Developer Nonindustrial source; Transcend Therapeutics [CEASED]
  • Class Reducing agents; Small molecules
  • Mechanism of Action Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Amyotrophic lateral sclerosis; Atherosclerosis; Cardiovascular disorders; Dermatitis; HIV-1 infections; Multiple organ failure

Most Recent Events

  • 18 Jun 2001 No-Development-Reported for Amyotrophic lateral sclerosis in USA (IV)
  • 18 Jun 2001 No-Development-Reported for Amyotrophic lateral sclerosis in USA (PO)
  • 18 Jun 2001 No-Development-Reported for Multiple organ failure in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top